Zoetis Inc. (ZOE.DE)
EUR 138.68
(1.2%)
EUR 138.68
(1.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.22 Billion USD | 11.15% |
| 2022 | 2.88 Billion USD | 4.83% |
| 2021 | 2.75 Billion USD | 20.41% |
| 2020 | 2.28 Billion USD | 10.27% |
| 2019 | 2.07 Billion USD | 10.31% |
| 2018 | 1.88 Billion USD | 9.04% |
| 2017 | 1.72 Billion USD | 23.48% |
| 2016 | 1.39 Billion USD | 30.56% |
| 2015 | 1.07 Billion USD | 10.42% |
| 2014 | 969 Million USD | 18.17% |
| 2013 | 820 Million USD | -1.2% |
| 2012 | 830 Million USD | 31.33% |
| 2011 | 632 Million USD | 120.21% |
| 2010 | 287 Million USD | 33.49% |
| 2009 | 215 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 801 Million USD | 8.1% |
| 2024 Q2 | 906 Million USD | 17.48% |
| 2023 FY | 3.21 Billion USD | 11.15% |
| 2023 Q3 | 792 Million USD | -15.57% |
| 2023 Q2 | 938 Million USD | 20.1% |
| 2023 Q4 | 741 Million USD | -6.44% |
| 2023 Q1 | 781 Million USD | 19.05% |
| 2022 Q3 | 738 Million USD | 1.93% |
| 2022 FY | 2.88 Billion USD | 4.83% |
| 2022 Q1 | 793 Million USD | 41.35% |
| 2022 Q2 | 724 Million USD | -8.7% |
| 2022 Q4 | 656 Million USD | -11.11% |
| 2021 Q1 | 755 Million USD | 47.17% |
| 2021 Q4 | 561 Million USD | -22.94% |
| 2021 FY | 2.75 Billion USD | 20.41% |
| 2021 Q3 | 728 Million USD | 0.55% |
| 2021 Q2 | 724 Million USD | -4.11% |
| 2020 Q2 | 553 Million USD | 2.6% |
| 2020 Q1 | 539 Million USD | 7.8% |
| 2020 Q3 | 664 Million USD | 20.07% |
| 2020 Q4 | 513 Million USD | -22.74% |
| 2020 FY | 2.28 Billion USD | 10.27% |
| 2019 Q2 | 526 Million USD | 22.9% |
| 2019 Q4 | 500 Million USD | -11.35% |
| 2019 Q3 | 564 Million USD | 7.22% |
| 2019 FY | 2.07 Billion USD | 10.31% |
| 2019 Q1 | 428 Million USD | -1.83% |
| 2018 Q1 | 461 Million USD | -9.43% |
| 2018 Q4 | 436 Million USD | -12.8% |
| 2018 FY | 1.88 Billion USD | 9.04% |
| 2018 Q3 | 500 Million USD | 3.31% |
| 2018 Q2 | 484 Million USD | 4.99% |
| 2017 FY | 1.72 Billion USD | 23.48% |
| 2017 Q1 | 367 Million USD | 15.05% |
| 2017 Q4 | 509 Million USD | 9.46% |
| 2017 Q2 | 384 Million USD | 4.63% |
| 2017 Q3 | 465 Million USD | 21.09% |
| 2016 Q4 | 319 Million USD | -14.93% |
| 2016 FY | 1.39 Billion USD | 30.56% |
| 2016 Q3 | 375 Million USD | 5.34% |
| 2016 Q2 | 356 Million USD | 2.59% |
| 2016 Q1 | 347 Million USD | 52.19% |
| 2015 FY | 1.07 Billion USD | 10.42% |
| 2015 Q3 | 313 Million USD | 15.93% |
| 2015 Q2 | 270 Million USD | 4.25% |
| 2015 Q1 | 259 Million USD | 33.51% |
| 2015 Q4 | 228 Million USD | -27.16% |
| 2014 Q2 | 242 Million USD | -6.92% |
| 2014 FY | 969 Million USD | 18.17% |
| 2014 Q4 | 194 Million USD | -28.94% |
| 2014 Q3 | 273 Million USD | 12.81% |
| 2014 Q1 | 260 Million USD | 34.02% |
| 2013 Q1 | 226 Million USD | 47.71% |
| 2013 Q2 | 189 Million USD | -16.37% |
| 2013 Q3 | 211 Million USD | 11.64% |
| 2013 Q4 | 194 Million USD | -8.06% |
| 2013 FY | 820 Million USD | -1.2% |
| 2012 FY | 830 Million USD | 31.33% |
| 2012 Q1 | 198 Million USD | 37.5% |
| 2012 Q2 | 264 Million USD | 33.33% |
| 2012 Q4 | 153 Million USD | -28.84% |
| 2012 Q3 | 215 Million USD | -18.56% |
| 2011 Q1 | 150 Million USD | 0.0% |
| 2011 Q3 | 201 Million USD | 46.72% |
| 2011 Q2 | 137 Million USD | -8.67% |
| 2011 Q4 | 144 Million USD | -28.36% |
| 2011 FY | 632 Million USD | 120.21% |
| 2010 FY | 287 Million USD | 33.49% |
| 2009 FY | 215 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| MPH Health Care AG | 15.7 Million EUR | -20415.924% |
| Apontis Pharma AG | -15.1 Million EUR | 21431.126% |
| Dermapharm Holding SE | 182.89 Million EUR | -1661.129% |
| Evotec SE | -47.5 Million EUR | 6880.053% |
| MERCK Kommanditgesellschaft auf Aktien | 3.6 Billion EUR | 10.751% |
| PharmaSGP Holding SE | 40.91 Million EUR | -7772.611% |
| SynBiotic SE | -7.58 Million EUR | 42582.452% |